CLNN
Price
$2.97
Change
-$0.20 (-6.31%)
Updated
Apr 25, 04:59 PM (EDT)
Capitalization
27.36M
GOSS
Price
$0.95
Change
-$0.03 (-3.06%)
Updated
Apr 25, 04:59 PM (EDT)
Capitalization
222.5M
18 days until earnings call
Ad is loading...

CLNN vs GOSS

Header iconCLNN vs GOSS Comparison
Open Charts CLNN vs GOSSBanner chart's image
Clene
Price$2.97
Change-$0.20 (-6.31%)
Volume$600
Capitalization27.36M
Gossamer Bio
Price$0.95
Change-$0.03 (-3.06%)
Volume$9.35K
Capitalization222.5M
CLNN vs GOSS Comparison Chart
Loading...
CLNN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GOSS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CLNN vs. GOSS commentary
Apr 25, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CLNN is a Hold and GOSS is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 25, 2025
Stock price -- (CLNN: $3.17 vs. GOSS: $0.98)
Brand notoriety: CLNN and GOSS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CLNN: 737% vs. GOSS: 95%
Market capitalization -- CLNN: $27.36M vs. GOSS: $222.5M
CLNN [@Biotechnology] is valued at $27.36M. GOSS’s [@Biotechnology] market capitalization is $222.5M. The market cap for tickers in the [@Biotechnology] industry ranges from $275.91B to $0. The average market capitalization across the [@Biotechnology] industry is $2.16B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CLNN’s FA Score shows that 0 FA rating(s) are green whileGOSS’s FA Score has 0 green FA rating(s).

  • CLNN’s FA Score: 0 green, 5 red.
  • GOSS’s FA Score: 0 green, 5 red.
According to our system of comparison, GOSS is a better buy in the long-term than CLNN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CLNN’s TA Score shows that 5 TA indicator(s) are bullish while GOSS’s TA Score has 5 bullish TA indicator(s).

  • CLNN’s TA Score: 5 bullish, 3 bearish.
  • GOSS’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, CLNN is a better buy in the short-term than GOSS.

Price Growth

CLNN (@Biotechnology) experienced а +5.67% price change this week, while GOSS (@Biotechnology) price change was +16.23% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.17%. For the same industry, the average monthly price growth was -4.24%, and the average quarterly price growth was -12.55%.

Reported Earning Dates

CLNN is expected to report earnings on Mar 24, 2025.

GOSS is expected to report earnings on Aug 12, 2025.

Industries' Descriptions

@Biotechnology (+7.17% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
GOSS($222M) has a higher market cap than CLNN($27.4M). GOSS YTD gains are higher at: 8.247 vs. CLNN (-40.301). CLNN has higher annual earnings (EBITDA): -29.61M vs. GOSS (-39.97M). GOSS has more cash in the bank: 295M vs. CLNN (14.6M). CLNN has less debt than GOSS: CLNN (22.9M) vs GOSS (203M). GOSS has higher revenues than CLNN: GOSS (115M) vs CLNN (421K).
CLNNGOSSCLNN / GOSS
Capitalization27.4M222M12%
EBITDA-29.61M-39.97M74%
Gain YTD-40.3018.247-489%
P/E RatioN/AN/A-
Revenue421K115M0%
Total Cash14.6M295M5%
Total Debt22.9M203M11%
FUNDAMENTALS RATINGS
CLNN vs GOSS: Fundamental Ratings
CLNN
GOSS
OUTLOOK RATING
1..100
7514
VALUATION
overvalued / fair valued / undervalued
1..100
84
Overvalued
63
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9996
PRICE GROWTH RATING
1..100
9362
P/E GROWTH RATING
1..100
95100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

GOSS's Valuation (63) in the Pharmaceuticals Major industry is in the same range as CLNN (84) in the null industry. This means that GOSS’s stock grew similarly to CLNN’s over the last 12 months.

GOSS's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as CLNN (100) in the null industry. This means that GOSS’s stock grew similarly to CLNN’s over the last 12 months.

GOSS's SMR Rating (96) in the Pharmaceuticals Major industry is in the same range as CLNN (99) in the null industry. This means that GOSS’s stock grew similarly to CLNN’s over the last 12 months.

GOSS's Price Growth Rating (62) in the Pharmaceuticals Major industry is in the same range as CLNN (93) in the null industry. This means that GOSS’s stock grew similarly to CLNN’s over the last 12 months.

CLNN's P/E Growth Rating (95) in the null industry is in the same range as GOSS (100) in the Pharmaceuticals Major industry. This means that CLNN’s stock grew similarly to GOSS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CLNNGOSS
RSI
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
85%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
72%
Bullish Trend 2 days ago
83%
Momentum
ODDS (%)
Bullish Trend 2 days ago
75%
Bullish Trend 2 days ago
81%
MACD
ODDS (%)
Bullish Trend 2 days ago
73%
Bullish Trend 2 days ago
80%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
67%
Bullish Trend 2 days ago
83%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
88%
Advances
ODDS (%)
Bullish Trend 17 days ago
79%
Bullish Trend 2 days ago
84%
Declines
ODDS (%)
Bearish Trend 3 days ago
89%
Bearish Trend 22 days ago
88%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
83%
Aroon
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
88%
View a ticker or compare two or three
Ad is loading...
CLNN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GOSS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ACSLX77.85N/A
N/A
American Century Select C
UBPIX13.51N/A
N/A
ProFunds UltraLatin America Inv
LMOPX28.61N/A
N/A
Patient Opportunity C
DHPYX15.87N/A
N/A
Diamond Hill Mid Cap Y
PRCNX10.36N/A
N/A
T. Rowe Price Intl Disciplined Eq Inv

CLNN and

Correlation & Price change

A.I.dvisor tells us that CLNN and KZIA have been poorly correlated (+33% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CLNN and KZIA's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CLNN
1D Price
Change %
CLNN100%
+12.01%
KZIA - CLNN
33%
Poorly correlated
+2.78%
GOSS - CLNN
30%
Poorly correlated
+9.43%
BMRN - CLNN
29%
Poorly correlated
+1.29%
QNCX - CLNN
29%
Poorly correlated
+6.13%
VRNA - CLNN
28%
Poorly correlated
+2.32%
More